Context: Total pancreatectomy and intrahepatic islet autotransplantation (TP/IAT) is performed to alleviate severe abdominal pain, avoid narcotic use, maintain islet function, and avoid diabetes in patients with chronic pancreatitis. However, many TP/IAT recipients complain of postprandial hypoglycemia.
S
evere unrelenting pain from chronic pancreatitis is a debilitating condition that leads to narcotic dependence and low quality of life (1) (2) (3) (4) . Since 1980, total pancreatectomy and intrahepatic islet autotransplantation (TP/IAT) has proven to be effective at resolving pain, improving quality of life, and avoiding diabetes when other treatments have failed (4) (5) (6) (7) (8) (9) (10) . However, only recently has it been recognized that many TP/IAT recipients report symptoms of hypoglycemia after consuming a high-carbohydrate meal (11) . Continuous glucose monitoring demonstrated that recipients experience blood glucose concentrations as low as 37 mg/dL (11) . This situation can lead to repeated bouts of hypoglycemia and consequent symptom desensitization to low glucose levels (12, 13) , which is extremely dangerous.
The surgical procedure for total pancreatectomy often includes Roux-en-Y choledocho-jejunostomy and gastroor (if pylorus-spared) duodeno-jejunostomy (4), which alter food and nutrient absorption and may play a role in postprandial hypoglycemia. Patients undergoing Rouxen-Y gastric bypass (GB) have also shown abnormally high then low postprandial blood glucose levels (14) . We have reported that high carbohydrate meal-induced hypoglycemia is common and has forced many recipients to reduce carbohydrate intake and to eat frequently during the day to avoid hypoglycemic episodes (11) . Under normal physiologic conditions, postprandial normoglycemia is maintained by precise coordination between insulin and glucagon secretion. Glucose levels rise after meals, and insulin is secreted to decrease blood glucose levels via tissue-glucose uptake. If postprandial blood glucose levels fall below normal, glucagon is secreted, causing liver glycogenolysis to release free glucose into the systemic circulation to increase blood glucose levels. We have suggested that intrahepatically transplanted islets are surrounded by milieu high in glucose during glycogenolysis and that this might inhibit their glucagon response to hypoglycemia occurring in the systemic circulation (11, 15) .
In this study, we examined whether abnormalities in insulin or glucagon secretion or in regulation of hepatic glucose production, glucose absorption, or disposal contribute to hypoglycemia that recipients experience after consuming a high-carbohydrate meal. Fasted TP/IAT recipients and control subjects consumed a mixed meal containing 70 g of glucose labeled with [1- 13 C] while receiving infusions containing [6,6- 2 H 2 ]-glucose and [6-3 H]-glucose. The use of these three tracers allowed determination of rates of appearance and disappearance of the meal as well as endogenous glucose production (EGP) (16) .
Materials and Methods

Subjects
After approval from the Mayo Institutional Review Board, 10 (eight female, two male) TP/IAT recipients and 10 age-, sex-, and body mass index-matched control subjects gave written informed consent to participate in the study. Seven of 10 recipients had a history of postprandial hypoglycemia. Tables 1  and 2 list the subject characteristics. All recipients had autoislets infused into the hepatic portal vein (intrahepatic), and one of the recipients additionally had intraperitoneal islet placement (intrahepatic + intraperitoneal) because the pressure in the hepatic portal vein became too high to safely infuse all the islets into the liver. All recipients had either a Roux-en-Y or duodenojejunostomy during the TP/IAT procedure. None of the recipients used exogenous insulin. Body composition was measured using dual-energy X-ray absorptiometry (DPX scanner; Lunar, Madison, WI).
Experimental design
Subjects were studied using a labeled mixed meal at the Clinical Research Unit at the Mayo Clinic (Rochester, MN). Participants were admitted to the Clinical Research Unit at 5 PM the night before the study and consumed a standardized meal (10 kcal/kg body weight: 40% carbohydrate, 30% fat, and 30% protein) and then fasted overnight. At 6:30 AM (2180 minutes), an 18-gauge needle was inserted into a forearm vein for infusions unless the subject had a port that was used instead. An H 2 ]-glucose was initiated to measure fasting EGP. At time 0 (9:30 AM), subjects consumed a meal consisting of two scrambled eggs, 50 g of Canadian bacon, and Jell-O containing 70 g of glucose labeled with [1- 13 C] (4% enrichment) to trace the systemic appearance of ingested glucose. This meal provided 510 kcal (61% carbohydrate, 19% protein, and 21% fat). An infusion of [6- 3 H]-glucose was started at this time, and the infusion rate was varied to mimic the anticipated appearance of meal [1- 13 C]-glucose. The ratio of H]-glucose to [1- 13 C]-glucose was used to calculate meal appearance (17) . At time 0, the rate of infusion of [6,6-2 H 2 ]-glucose was decreased (from 0 to 10 minutes: 80% of basal rate; from 11 to 20 minutes: 60% of basal rate; from 21 to 40 minutes: 40% of basal rate; from 41 to 75 minutes: 30% of basal rate; from 76 to 260 minutes: 49% of basal rate; and from 261 to 360 minutes: 60% of basal rate) to approximate the anticipated fall in EGP, thereby minimizing changes in specific activity as previously described (17, 18) .
Analytical techniques and glucose turnover
Plasma samples were placed on ice, centrifuged at 4°C, separated, and stored at 220°C until assayed. Glucose concentrations were measured using a glucose oxidase method (Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin was measured using a chemiluminescence assay (Access Assay; Beckman Coulter, Chaska, MN). Plasma glucagon and C-peptide were measured by radio-immunoassay (EMD Millipore, Billerica, MA). Plasma [6, H 2 ]-glucose and [1-
13 C]-glucose enrichments were measured with gas chromatographic mass spectrometry (Thermoquest, San Jose, CA) to simultaneously monitor the C-1 and C-2 and the C-3 and C-6 fragments, as described by Beylot et al. (19) . In addition, H]-glucose specific activity was measured by liquid scintillation counting after deproteinization and passage over anion and cation exchange columns (18) .
Calculations
The systemic rates of meal appearance (R a meal ), EGP, and meal disappearance (R d ) were calculated using Steele non-steady-state equation (20 
Statistical Analysis
The effect of the meal on metabolic and hormonal parameters between groups was analyzed by Student t test. Within each group, the effect of the meal was analyzed by one-factor analysis of variance for repeated measures followed by Fisher protected least significant difference for individual paired comparisons (Statview; SAS Institute Inc., Cary, NC). Data in the text are presented as means 6 standard error of the mean. Statistical significance was considered at P , 0.05.
Results
Recipients were 5 6 1 years postislet autotransplantation (Table 2) . When comparing recipients and control subjects, there were no significant differences between age, body mass index, lean body mass, hemoglobin A1c, and fasting insulin. The only metabolic differences were that recipients had significantly lower C-peptide and higher fasting glucose levels compared with control subjects.
Comparisons of glucose, insulin, C-peptide, glucagon, EGP, rate of meal appearance, and rate of glucose disappearance of recipients and control subjects after meal consumption are provided in Table 3 . Although not apparent when plotting absolute glucose levels (Fig. 1A) , D glucose levels for recipients between minutes 240 to 360 were significantly lower than control subjects (P , 0.05) Data for recipients and control subjects are means 6 standard error. (Fig. 1B) . The mean glucose nadir for the recipient group as a whole was below the lower limits of normal (P = 0.04) (Fig. 1C) . Seven of the 10 recipients experienced abnormally low postprandial D glucose nadirs during the last 240 to 360 minutes postprandially (P , 0.001) (Fig. 1D) . Postprandial insulin and C-peptide levels were less in the recipients compared with control subjects ( Fig. 2A  and 2C ), but when corrected for the number of islets transplanted this relationship reversed such that insulin and C-peptide levels tended to be greater in the recipients [peak insulin: 162 6 29 (1127 6 198) vs 95 6 16 (659 6 110) uU/mL (pmol/L), P = 0.05; peak C-peptide: 18.6 6 3 (6.2 6 1.0) vs 13.8 6 0.9 (4.6 6 0.3) ng/mL (nmol/L), P = 0.17]) ( Fig. 2B and 2D ). D Glucagon remained unchanged in recipients despite their abnormal decreases in postprandial glucose (minutes 240 to 260, P = 0.58) (Figs. 1B,  1D, and 2F) .
The maximum rate of meal appearance was 97 6 14 mmol/kg/min for recipients and 78 6 8 mmol/kg/min for control subjects (P = 0.25) (Fig. 3A) . The maximum rate of meal disappearance was 106 6 15 mmol/kg/min for recipients and 87 6 8 mmol/kg/min for control subjects (P = 0.25) (Fig. 3B) . Fasting EGP was 16.4 6 0.8 mmol/kg/min for recipients and 16.0 6 0.5 mmol/kg/ min for control subjects (P = 0.67) (Fig. 3C) . EGP nadir was the same between recipients and control subjects (3.94 6 0.33 vs 3.73 6 0.28 mmol/kg/min, P = 0.63) (Fig. 3C) .
Discussion
The goal of this study was to assess possible mechanisms of postprandial hypoglycemia experienced by TP/IAT recipients. Baseline glucose levels were slightly higher in recipients, but peak postprandial glucose levels were markedly higher early after the meal. From 4 to 6 hours after the meal, however, seven recipients had abnormally low glucose levels (six of the seven recipients had a history of postprandial hypoglycemia). Insulin and C-peptide levels were lower in TP/IAT recipients compared with control subjects, but when these levels were adjusted for the number of islets transplanted, both levels were higher in the recipient group, assuming the controls had a mean islet number of 1 million. Glucagon levels remained unchanged in TP/IAT recipients despite abnormal decreases Abbreviations: AAB, area above basal; AUC, area under the curve.
Data for recipients and control subjects are means 6 standard error.
doi: 10.1210/jc.2017-02182 https://academic.oup.com/jcemin blood glucose 240 to 360 minutes after meal ingestion. No significant differences were found in the rates of meal appearance, glucose disappearance, and EGP in recipients and control subjects. Systemic insulin levels, after correction for the number of islets transplanted, were higher than in control subjects, which suggests that intrahepatically transplanted b-cells in recipients might be overly responsive to changes in glucose levels. This theoretically could happen if intrahepatic islets undergo priming by intrahepatic glucose flux as occurs during glucose-potentiation of acute glucose-induced insulin secretion (22, 23) . Late in the study (240 to 360 minutes postprandially), 7 of the 10 recipients had postprandial glucose values (D glucose nadir) below the normal range but did not have increased glucagon secretion as a response to reestablish normoglycemia. This is consistent with our previous studies demonstrating that intrahepatic islets do not secrete glucagon despite low systemic blood glucose levels during hypoglycemic clamps (24) . This surgical procedure for islet transplantation destroys the normal central nervous system provision of a-adrenergic modulation of b-and a-cell function. This deinnervation may be a contributing factor in the prolonged hypoglycemia recipients experience because an important function for a-adrenergic nerves during systemic hypoglycemia is to inhibit insulin secretion. Its absence could result in inadequate modulation of insulin secretion, which in turn could contribute to inappropriate increases in insulin secretion and consequent lowering of systemic glucose levels. GB for patients undergoing bariatric surgery has also been shown to alter glucose and insulin responses after meal ingestion (14) . TP/IAT recipients and patients undergoing GB have postprandial glucose levels that are increased compared with control subjects and have similarly enhanced insulin responses after meal ingestion (when the insulin responses in TP/IAT are corrected for islet number). Glucagon responses after a meal have been reported to be increased compared with control subjects in patients undergoing GB. However, the study of patients undergoing GB reported glucagon levels for only 120 minutes after meal ingestion (14) , whereas our study demonstrates that glucagon levels 4 to 6 hours after meal ingestion are lower than normal.
In summary, although TP/IAT is highly effective at reducing pain, improving quality of life, and preventing diabetes, many TP/IAT recipients experience postprandial hypoglycemia. To our knowledge no previous research has studied the potential cause(s) of hypoglycemia after meal ingestion in TP/IAT. We observed that, despite an abnormally low glucose nadir in recipients, glucagon levels did not increase. It is uncertain what initiates hypoglycemia. One possibility is that a temporal mismatch of glucose and insulin levels play a role. It is clear, however, that the deficient glucagon response in TP/IAT recipients could be a key contributor sustaining postprandial hypoglycemia. The main limitation of the study is the relatively small number of subjects studied. There was some heterogeneity in the upper gastrointestinal surgery accompanying pancreatectomy as well as time since islet transplantation, which may have contributed to betweensubject variation and obscured differences in postprandial glucose flux. Therefore, additional studies are required to more fully explore the intricacies between meal ingestion and hypoglycemia in TP/IAT recipients. A better understanding of these interrelationships will enable recipients and their physicians to better manage meal composition and frequency of feeding to avoid dangerous hypoglycemic episodes.
